Novo Nordisk Sues Eli Lilly Over Alleged Deceptive GLP-1 Drug Advertising
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging that the latter's television advertisements for its weight-loss drug Zepbound are misleading. The ads claim that users of Zepbound lost more weight on average than those using Novo’s Wegovy. However, Novo argues these claims rely on outdated data and point to a newer study showing improved results with an updated dose of Wegovy launched in April 2025. The lawsuit seeks to halt the ads and compel corrective advertising while also seeking compensation for lost profits due to misleading comparisons between Zepbound and Wegovy, as well as Mounjaro versus Ozempic. While potential financial damages may be limited given the recent product update by Novo Nordisk, a court order halting Eli Lilly's advertisements could significantly benefit Novo in terms of market perception. The GLP-1 drug sector remains highly competitive and lucrative, with tirzepatide-based drugs like Mounjaro and Zepbound becoming top-selling medications. The obesity medicine market is expected to grow from $66 billion in 2025 to over $120 billion by 2030.
Topics: advertising dispute GLP-1 drugs pharmaceuticals weight loss